BioPharm Insight, March 23, 2011, Anusha Kambhampaty
Cynapsus Therapeutics (CVE:CTH) is currently engaging in discussions with CROs to help run a Phase I study of lead agent APL-130277, a sublingual formulation of apomorphine, an approved agent used to treat “off-episodes” of patients with advanced Parkinson’s disease (PD), CEO Anthony Giovinazzo said. The Phase I trial is expected to initiate this July or August and the company will likely hire the CRO by June, Giovinazzo noted. MORE>>